Acadia Healthcare Co Inc
ACHC
ISIN null / Valor 14151414
Acadia Healthcare Co Inc
UMushroom community rating:
About company
Acadia Healthcare Co. Inc. is a publicly traded behavioral healthcare company headquartered in Franklin, Tennessee, that operates a network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and partial-hospitalization/intensive-outpatient programs, primarily across the United States. Its services cover a range of behavioral health needs including acute psychiatric care, substance use disorder treatment and programs for adolescents and adults, delivered through a mix of company-owned facilities, joint ventures and management arrangements; the company also deploys telehealth and other ancillary clinical services to extend care access. Acadia has grown through acquisitions and partnerships and focuses on clinical service delivery and facility operations within the behavioral health sector.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (19.05.2026):
Acadia Healthcare Co Inc's fourth quarter 2025 results show top-line growth but a large GAAP loss driven by a non‑cash goodwill impairment. Q4 revenue was $821.5 million (up 6.1% year‑over‑year), GAAP net loss per diluted share was $(13.02) (primarily reflecting a $996.2 million impairment), while adjusted measures were positive but down versus prior year (Q4 Adjusted EBITDA $99.8 million; adjusted net income $6.1 million or $0.07 per diluted share).
Revenue
Q4 2025 revenue: $821.5M, +6.1% YoY; full‑year 2025 revenue: $3,312.8M, +5.0% YoY. Same‑facility revenue rose 4.4% in Q4, driven by a 3.1% increase in patient days and a 1.3% increase in revenue per patient day.
GAAP Loss and Impairment
Acadia reported a Q4 2025 GAAP net loss attributable per diluted share of $(13.02) and a full‑year 2025 GAAP net loss per diluted share of $(12.16), primarily due to a $996.2M non‑cash goodwill impairment recorded in Q4.
Adjusted Results
Q4 2025 Adjusted EBITDA was $99.8M (versus $153.1M in Q4 2024) and included a $52.7M adjustment to professional & general liability (PLGL) reserves. Q4 adjusted net income was $6.1M ($0.07 diluted) versus $59.2M ($0.64) a year ago. Full‑year 2025 Adjusted EBITDA was $608.9M and adjusted net income was $182.7M ($2.00 diluted).
Operational Metrics
Q4 total facility admissions increased 7.2% YoY to 52,170 and total facility revenue per patient day rose 1.5% to $1,012. Same‑facility adjusted EBITDA declined 19.8% in the quarter to $152.0M.
Development and Capacity Growth
Acadia added 181 licensed beds in Q4 2025 (37 to existing facilities, 144 from new facilities). For full‑year 2025 the company added 1,089 licensed beds (311 to existing facilities, 778 from new facilities) and opened 15 new Comprehensive Treatment Centers during the year.
Balance Sheet & Cash
As of year‑end, cash and cash equivalents were $133.2M. Long‑term debt was $2.472B and total assets were $5.527B; accumulated deficit was $(765.8)M reflecting the impairment and other items.
2026 Guidance (Full Year & Q1)
Full‑year 2026 guidance: revenue $3.37–$3.45B, Adjusted EBITDA $575–$610M, adjusted diluted EPS $1.30–$1.55. Key assumptions include same‑facility volume growth of 0–1%, same‑facility revenue per patient day growth of 2–3%, interest expense of $157–$162M, and total bed additions of 400–600. Q1 2026 guidance factors in ~$14M of startup losses and recognition of $11M in supplemental FY2025 payments.
Management
The release notes that Debbie Osteen has joined Acadia as Chief Executive Officer (announced alongside the Q4 2025 results).
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
2318 M
Market cap (USD)
3,924,930
Daily traded volume (Shares)
39.05 / 37.2
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
